SNDL (SNDL) Stock Price

SNDL Price

NASDAQ·CLOSED
1.80
​
Market closed

Revenue has compounded at 77.4% per year over the past 8 years to 946.40 M CAD. SNDL's net margin stands at -1.7%, up from -404.4% several years earlier. Analysts set a median price target of 5.01 CAD, implying 178.5% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

SNDL stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SNDL business model & stock analysis

Sundial Growers, Inc. generates revenue through the production and distribution of cannabis products under the Sundial Cannabis brand. The company sells premium cannabis for adult use, including dried flower, pre-rolls, oils, capsules, and sublingual products, targeting consumers seeking both recreational and medicinal options. Their purpose-built indoor modular grow rooms ensure consistent quality across all product lines, catering to a market segment focused on premium, controlled cultivation. The firm's products are designed for use as prescription medicines and to enhance social, spiritual, and recreational occasions, directly appealing to adult consumers in the legal cannabis market. Sundial Growers, Inc. operates within the cannabis industry, focusing on the adult-use market with a brand dedicated to premium quality. The company's product portfolio includes dried flower cannabis, pre-rolls, oils, capsules, and sublingual formats, all marketed under the Sundial Cannabis name. These products are distributed to consumers who value consistent, high-quality cannabis for both medicinal and recreational purposes, reflecting the company's emphasis on controlled indoor cultivation. The business model relies on direct sales of branded products to end users in the legal adult-use cannabis sector. The company's revenue streams are derived from the sale of Sundial Cannabis-branded products, which are produced in purpose-built indoor modular grow rooms to maintain consistency. These products serve dual purposes as prescription medicines and for social, spiritual, and recreational use, targeting a broad segment of adult consumers. Sundial Growers, Inc. does not mention other brands or third-party partnerships, focusing solely on its own product line for the adult-use market.

Frequently asked questions about SNDL

Analysts currently set an average price target of 5.01 CAD for the SNDL stock (median: 5.01 CAD), implying +196.6 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the SNDL stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SNDL to generate revenue of 912.75 M CAD and earnings per share of -0.39 CAD.

Converted at the current exchange rate, the SNDL share trades at 1.14 EUR (1.80 CAD).

The SNDL share (SNDL) is listed on 5 stock exchanges, including: NASDAQ (SNDL), Frankfurt (14K.F), München (14K.MU), Düsseldorf (14K.DU), Hamburg (14K.HM).

The expected revenue of SNDL is 912.75 M CAD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SNDL is -103.56 M CAD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SNDL is currently -4.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SNDL stock.

The price-to-sales ratio (P/S) of SNDL is currently 0.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SNDL stock.

The Eulerpool Quality Score for SNDL is 2/10.

The ISIN of SNDL is CA83307B1013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of SNDL is A2PPQ6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of SNDL is SNDL. The ticker symbol is used to trade SNDL shares on the stock exchange.

Fair ValueTerminal
1.58 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
473.20 M CAD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CAD
Initial public offering
Aug 1, 2019
ISIN
CA83307B1013
Cusip
86730L109
Sedol
BJV2RL7
Market capitalization
475.55 M CADSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-4.58
P/Ee 2027
-83.92
P/Ee 2028
44.35
P/Ee 2029
16.33
P/Ee 2030
8.55
P/S
P/Se
0.52
EV/EBIT
—
P/B Ratio
0.43
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.24 %
Last updated Nov 22, 2026, 3:42 AM

SNDL Ticker

DÜSSELDORF · 14K.DUFRANKFURT · 14K.FHAMBURG · 14K.HMMUNICH · 14K.MUNASDAQ · SNDL

All fundamentals and in-depth analysis of SNDL

Our stock analysis for SNDL stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SNDL. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.